All In Biotech

Drug Trial Radar · NCT07843264

PPI Dosing Per CYP2C19 Genotype

A Pilot Study to Assess Healing of Erosive Esophagitis in Patients Randomized to Conventional PPI Doses Versus Dosing Based on CYP2C19 Genotype

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Dec 31, 2027

Study completion Apr 1, 2028

Sponsor

Lead sponsor
University of FloridaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.

Conditions

  • Gastroesophageal Reflux Disease With Esophagitis

Interventions

  • CYP2C19 based dosing Proton Pump InhibitorsDrug

    Pantoprazole dosing based on CYP2C19 phenotypes

  • Conventional proton pump inhibitor doseDrug

    conventional PPI dose of Pantoprazole 40 mg once or twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement of Los Angeles (LA) classification of Erosive Esphagitis (EE) gradeTime frame: 8 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UF Health

    Jacksonville, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.